← SynDRA
ELIMUSERTIB
SynDRA canonical compound SYN0040097 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | ATR |
| Mechanism of action | ATR kinase inhibitor |
All known targets
Mechanisms of action (all sources)
- ATR inhibitor
- Serine-protein kinase ATR inhibitor
- ATR kinase inhibitor
Cross-references
Synonyms
- 4-(1-METHYL-1H-PYRAZOL-5-YL)-2-[(3R)-3-METHYLMORPHOLIN-4-YL]-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE HYDROCHLORIDE
- BAY-1895344
- BAY1895344
- ELIMUSERTIB (BAY-1895344)
- YBXRSCXGRPSTMW-CYBMUJFWSA-N
- BAY 1895344
- (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine
- UNII-7N13IK9LNH
- 7N13IK9LNH
- SCHEMBL17501318
- MolPort-044-756-215
- EX-A1662
- AKOS032953592
- ACN-051236
- AC-30337
- AK688481
- (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine
- RefChem:136505
- ATR Inhibitor BAY1895344
- ATR Kinase Inhibitor BAY1895344
- Elimusertib (BAY-1895344)
- MFCD31561442
- Elimusertib free base
- ELIMUSERTIB [INN]
- ELIMUSERTIB [WHO-DD]
- orb1299925
- SCHEMBL21756640
- SCHEMBL29569580
- SCHEMBL30200285
- C20H21N7O
- GTPL10354
- NSC800525
- NSC817275
- s9864
- BAY-1895344 HCl(Elimusertib)?
- EBC-510506
- NSC-800525
- NSC-817275
- NCGC00510268-02
Look up ELIMUSERTIB in the interactive SynDRA portal →